Han Yu Pharmaceutical: Signed a series of commercial agreements with Sansei Madi, expecting annual peak sales of 30 million doses of weight loss drugs.

On August 19th, HanYu Pharmaceuticals and Zhejiang Sansheng Mandi Pharmaceuticals Co., Ltd. officially signed a series of commercial documents in Beijing, including the "Contract Manufacturing and Supply Agreement" and "Quality Agreement" for the Sumaglutide Injection. According to the agreement, the supply price will be based on non-binding sales forecasts, with costs calculated and quoted in stages for annual purchase quantities of 500 million units, 500-1000 million units, and >1000 million units. The peak annual sales are expected to reach 30 million units. The Sumaglutide Injection, which is the product of this collaboration, is classified as a Category 2.2 improved new drug and will be manufactured simultaneously in China and the United States.